Farxiga Lawyers No Longer Reviewing New Cases

The product liability lawyers at Saiontz & Kirk, P.A. are no longer pursuing additional Farxiga cases. Lawsuits were previously evaluated for individuals who have suffered kidney failure, a heart attack, stroke or been hospitalized due to ketoacidosis following use of this new diabetes drug. This page is maintained for informational purposes only.

RELATED CASES: Potential Invokana lawsuits are still being evaluated for individuals who have experienced amputation problems following use of this similar diabetes drug.

Farxiga (dapagliflozin) was introduced by AstraZeneca in 2014 for treatment of type 2 diabetes. It is part of the same class of medications as Invokana, which has been linked to reports of serious and potentially life-threatening risks. It appears that users may face a similar risk of Farxiga side effects that were not adequately disclosed on the drug warning label.

Potential Farxiga lawsuits were evaluated for individuals who suffered:

  • Kidney Failure
  • Heart Attack
  • Stroke
  • Ketoacidosis
  • Wrongful Death

New cases are no longer being accepted. This page is maintained for informational purposes only.

Farxiga Kidney Failure and Ketoacidosis Problems

Farxiga was approved by the FDA in 2014, after it was originally rejected three years earlier due to a lack of information on the safety and efficacy of the drug.

It is a member of a new class of diabetes drugs introduced in recent years, known as sodium-glucose co-transporter 2 (SGLT2) inhibitors.

The approval of Farxiga followed the approval of the Invokana as the first SGLT2 inhibitor in March 2013. As more individuals begin to use these new medications, signals of serious health risks have begun to emerge.

Farxiga and other SGLT2 inhibitors works by changing some normal kidney functions to increase the amount of sugar excreted in the urine. This was designed to increase glucose production and lower blood glucose levels among diabetics.

Although it appears that the drug makers knew or should have known about the potential injury risks with Farxiga before the medication was introduced, lawsuits will allege that AstraZeneca failed to adequately warn about all potential side effects.

SGLT2 inhibitors like Farxiga have been linked to hundreds of adverse event reports, including reports of:

  • Kidney Failure
  • Kidney Impairment
  • Kidney Stones
  • Urinary Tract Infections
  • Abnormal Weight Loss
  • Hypersensitivity Reactions

In addition, the FDA has expressed concerns that Farxiga may increase the risk of bladder cancer, causing the U.S. regulatory agency to initially reject the drug two years before it was approved.

Less than two years after Farxiga hit the market, the FDA issued a drug safety communication in May 2015, warning about reports of potential problems with Farxiga and other sodium-glucose co-transporter 2 (SGLT2) inhibiting diabetes drugs. The warning indicated that that the medication may cause patients to experience high levels of acid to accumulate in the blood; known as diabetic ketoacidosis, acidosis or ketosis.

In December 2015, the FDA expanded that Farxiga warning, urging patients to stop using the drug immediately and seek medical assistance if they began experiencing signs of ketoacidosis, like:

  • Difficulty Breathing
  • Nausea or Vomiting
  • Abdominal Pain
  • Confusion, Fatigue or Sleepiness

The FDA highlighted at least 73 adverse event reports received involving ketoacidosis with Farxiga or other similar diabetes drugs. Each of the cases resulted in hospitalization or emergency room treatment.

Allegations To Be Raised in Farxiga Lawsuits

  • Failure to Study Farxiga Side Effects;
  • Failure to Warn about Risk of Ketoacidosis, Heart Attacks, Strokes or Kidney Failure from Farxiga;
  • Misrepresenting the Safety of Farxiga;
  • Failure to Issue an Farxiga Recall

Farxiga Class Action Lawyers

The makers of Farxiga appear to have placed their desire for profits before consumer safety, by rushing the drug to market to gain an advantage over other competitor diabetes drugs. Financial compensation was pursued through a Farxiga class action lawsuit or individual injury claim for individuals hospitalized due to ketoacidosis or diagnosed with kidney failure, a heart attack or stroke.

New cases are no longer being accepted. This page is maintained for informational purposes only.